Mathematical model predicts resistance to Herceptin

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 8
Volume 18
Issue 8

Researchers at the University of Edinburgh in Scotland have built a mathematical model to determine the role of PTEN protein expression on resistance to trastuzumab (Herceptin).

Researchers at the University of Edinburgh in Scotland have built a mathematical model to determine the role of PTEN protein expression on resistance to trastuzumab (Herceptin).

Dana Faratian, MD, and colleagues used 56 differential equations to analyze the change in concentrations of 56 separate biological entities including proteins and lipid second messengers.

They worked with 122 breast cancers treated with trastuzumab and found that quantitative PTEN protein expression was a key determinant of who would be resistant or sensitive to trastuzumab. In addition, using the mathematical modeling techniques, the absence of PTEN was more predictive than could be determined using standard multivariate or laboratory analysis (Cancer Res online, July 21, 2009).

The results help explain why some patients still fail on tratuzumab, commented Sofia Merajver, MD, PhD, a Cancer Research editoral board member.

Related Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
4 KOLs are featured in this panel.
Related Content